APA

Meiners P. M., Vissink A., Kroese F. G. M., Spijkervet F. K. L., Smitt-Kamminga N. S., Abdulahad W. H., Bulthuis-Kuiper J., Brouwer E., Arends S. & Bootsma H. (20140818). Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). : Annals of the rheumatic diseases.

Chicago

Meiners P M, Vissink A, Kroese F G M, Spijkervet F K L, Smitt-Kamminga N Sillevis, Abdulahad W H, Bulthuis-Kuiper J, Brouwer E, Arends S and Bootsma H. 20140818. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). : Annals of the rheumatic diseases.

Harvard

Meiners P. M., Vissink A., Kroese F. G. M., Spijkervet F. K. L., Smitt-Kamminga N. S., Abdulahad W. H., Bulthuis-Kuiper J., Brouwer E., Arends S. and Bootsma H. (20140818). Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). : Annals of the rheumatic diseases.

MLA

Meiners P M, Vissink A, Kroese F G M, Spijkervet F K L, Smitt-Kamminga N Sillevis, Abdulahad W H, Bulthuis-Kuiper J, Brouwer E, Arends S and Bootsma H. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). : Annals of the rheumatic diseases. 20140818.